MX356129B - Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos. - Google Patents

Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.

Info

Publication number
MX356129B
MX356129B MX2014004271A MX2014004271A MX356129B MX 356129 B MX356129 B MX 356129B MX 2014004271 A MX2014004271 A MX 2014004271A MX 2014004271 A MX2014004271 A MX 2014004271A MX 356129 B MX356129 B MX 356129B
Authority
MX
Mexico
Prior art keywords
tissue
peptide analogs
preventing
disorders associated
treating diseases
Prior art date
Application number
MX2014004271A
Other languages
English (en)
Inventor
Cerami Anthony
Brines Michael
Original Assignee
Araim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araim Pharmaceuticals Inc filed Critical Araim Pharmaceuticals Inc
Publication of MX356129B publication Critical patent/MX356129B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)

Abstract

La presente invención se refiere a péptidos y análogos de péptidos que tienen actividades protectoras de los tejidos mientras que tienen poco o ningún efecto hematopoyético potencialmente indeseable. Los péptidos y análogos de péptidos son útiles para evitar y tratar una variedad de padecimientos y desórdenes asociados con daño de los tejidos.
MX2014004271A 2008-01-22 2009-01-22 Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos. MX356129B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6201208P 2008-01-22 2008-01-22
US6202208P 2008-01-22 2008-01-22
US6204508P 2008-01-22 2008-01-22
US13391208P 2008-07-03 2008-07-03
US20389008P 2008-12-30 2008-12-30
PCT/US2009/000424 WO2009094172A2 (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Publications (1)

Publication Number Publication Date
MX356129B true MX356129B (es) 2018-05-16

Family

ID=40810017

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014004271A MX356129B (es) 2008-01-22 2009-01-22 Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
MX2010008050A MX2010008050A (es) 2008-01-22 2009-01-22 Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
MX2019011592A MX2019011592A (es) 2008-01-22 2010-07-22 Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2010008050A MX2010008050A (es) 2008-01-22 2009-01-22 Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
MX2019011592A MX2019011592A (es) 2008-01-22 2010-07-22 Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.

Country Status (15)

Country Link
US (4) US8853358B2 (es)
EP (2) EP2933264A3 (es)
JP (5) JP5542064B2 (es)
KR (7) KR20200075044A (es)
CN (4) CN102066413B (es)
AU (1) AU2009206748B2 (es)
CA (1) CA2712757A1 (es)
ES (1) ES2539124T3 (es)
HK (1) HK1215713A1 (es)
IL (1) IL207155A (es)
MX (3) MX356129B (es)
NZ (3) NZ621196A (es)
PL (1) PL2245056T4 (es)
SG (3) SG10201604530SA (es)
WO (1) WO2009094172A2 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
PL2540309T3 (pl) 2005-08-05 2018-03-30 Araim Pharmaceuticals, Inc. Peptydy chroniące tkanki i ich zastosowanie
JP5542064B2 (ja) 2008-01-22 2014-07-09 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
WO2011127144A1 (en) 2010-04-06 2011-10-13 Synedgen Inc. Methods and compositions for treating wounds utilizing chitosan compounds
US9999702B2 (en) * 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
WO2012069474A2 (en) 2010-11-24 2012-05-31 H. Lundbeck A/S A method for reducing potential virus burden in a sample by cyanate treatment
US20130288373A1 (en) * 2010-12-20 2013-10-31 Kenneth Verstraete Crystal structure of flt3 ligand-receptor complex
ES2633343T3 (es) * 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal
FR2978964B1 (fr) 2011-08-09 2015-02-20 Conservatoire Nat Arts Composition vaccinale anti-il-6
JP6426001B2 (ja) * 2011-11-17 2018-11-21 グリア エスピー ゼット．オー．オー． 神経膠腫を治療するための組成物および方法
CN105012313B (zh) * 2014-04-25 2018-03-16 广州市赛普特医药科技股份有限公司 5α‑雄甾‑3β,5,6β‑三醇及其类似物在预防或治疗低压缺氧引起的高原病中的应用
AU2013317871B2 (en) * 2012-09-20 2018-05-10 Synedgen, Inc. Methods for treatment or prevention of damage resulting from radiation, trauma or shock
US9895399B2 (en) * 2013-01-31 2018-02-20 The Trustees Of The University Of Pennsylvania Repair of peripheral nerve injury
US20160222084A1 (en) 2013-03-15 2016-08-04 The Board Of Regents Of The University Of Oklahoma Compositions Comprising D-Amino Acid Peptides and Methods of Production and Use Thereof for Inhibiting Autoantibodies
SG11201600294QA (en) * 2013-07-17 2016-02-26 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
KR101510743B1 (ko) 2013-07-23 2015-04-10 (주)케어젠 파골 세포 분화 억제용 펩타이드 및 이의 용도
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
GB2539161A (en) * 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
US20180292390A1 (en) * 2015-04-23 2018-10-11 Rowan University Novel slice cultures and methods for diagnosing neuronal degeneration diseases
CN105233256A (zh) * 2015-10-28 2016-01-13 中国人民解放军第三军医大学 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
RU2613308C1 (ru) * 2015-11-23 2017-03-15 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования предрасположенности к послеоперационному кровотечению при раке головки поджелудочной железы
JP7235509B2 (ja) 2016-04-14 2023-03-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 植え込み可能な生きた電極およびその製造方法
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3448415A4 (en) * 2016-04-29 2019-11-06 Araim Pharmaceuticals, Inc. TREATMENT-PROOFING PEPTIDES FOR THE PREVENTION AND TREATMENT OF DISEASES AND DISORDERS RELATED TO TISSUE DAMAGE
CN106075392B (zh) * 2016-07-18 2020-07-07 滨州医学院 促红细胞生成素衍生物在听力保护上的应用
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
CA3035561A1 (en) * 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders
KR102499651B1 (ko) * 2016-11-10 2023-02-13 에이에스씨 리제니티 리미티드 에리트로포이에틴-유래 분자를 함유하는 국소 적용을 위한 미용 제형
EP3587443A4 (en) * 2017-02-27 2021-02-17 Sylus Co., Ltd. USE OF ERYTHROPOIETIN PEPTIDE BY EFFECT ON CELL DAMAGE PREVENTION THEREOF
JP6450999B2 (ja) * 2017-03-31 2019-01-16 国立大学法人群馬大学 Ｂ型ボツリヌス毒素を用いたレイノー現象の治療
EP3619324B1 (en) * 2017-05-05 2025-07-09 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN107021996B (zh) * 2017-05-24 2020-02-14 中国海洋大学 一种短肽、其应用以及由其得到的抗菌组合物
AU2018321825A1 (en) * 2017-08-19 2020-03-05 Ohio State Innovation Foundation Novel peptide-based cancer imaging agents
US20200223894A1 (en) * 2017-09-19 2020-07-16 Auckland Uniservices Limited Peptides for the treatment of conditions associated with adiponectin dysfunction
CN107880109B (zh) * 2017-11-01 2019-08-30 复旦大学附属中山医院 一种促红细胞生成素来源肽及其制备方法和用途
US10975124B2 (en) 2018-02-23 2021-04-13 The Board Of Regents Of The University Of Oklahoma Methods and compositions for treating diseases and conditions associated with gonadotropin releasing hormone receptor
KR102167641B1 (ko) 2018-08-27 2020-10-19 주식회사 사이루스 에리스로포이에틴 유래 펩티드를 함유하는 세포증식 촉진용 조성물
CN113056286B (zh) 2018-09-10 2025-04-29 冷泉港实验室 用于治疗胰腺炎的方法
KR20200080179A (ko) * 2018-12-26 2020-07-06 아미코젠주식회사 아세틸콜린 수용체 저해 펩타이드 및 이의 용도
AU2020258086A1 (en) * 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
JP2023500702A (ja) * 2019-11-04 2023-01-10 ファラデイ ファーマシューティカルズ， インコーポレイテッド 化学療法に関連した悪液質および心毒性の治療ならびに予防のためのヨウ化化合物の使用
AU2021231655B2 (en) 2020-02-06 2024-02-15 Austin Star Detonator Company Integrated detonator sensors
KR102387136B1 (ko) * 2020-04-06 2022-04-14 재단법인대구경북과학기술원 탈모의 예방 또는 치료용 펩티드 및 이의 이용
WO2021245677A1 (en) * 2020-06-05 2021-12-09 Digestix Bioscience Inc. Compositions and methods for treating dysplastic and early-stage neoplastic conditions
CN111863118B (zh) * 2020-07-20 2023-09-05 湖南莱博赛医用机器人有限公司 基于tct制片进行tct和dna倍体分析的方法
CN112557347B (zh) * 2020-11-12 2023-10-24 渤海大学 一种黏液层中乳糜粒子迁移模型的制备及检测方法
US12492223B2 (en) 2021-07-23 2025-12-09 Lateral IP Pty Ltd Peptide compositions capable of binding lanthionine synthetase C-like protein (LanCl) and uses thereof
AU2022316237A1 (en) * 2021-07-23 2024-02-01 Lateral IP Pty Ltd Peptide compositions capable of binding lanthionine synthetase c-like protein (lancl) and uses thereof
CN114606317B (zh) * 2022-03-22 2022-12-02 中山大学附属第一医院 一种预测胃癌淋巴结转移的菌群标志物及其应用
CN117106057B (zh) * 2022-08-19 2024-11-01 南京汉欣医药科技有限公司 一种高纯的人促肾上腺皮质激素或其类似物及其规模化制备方法
GB202215797D0 (en) 2022-10-25 2022-12-07 Solasta Bio Ltd Insect neuropeptide analogues
CN116983469B (zh) * 2023-08-03 2025-11-21 东华大学 一种水凝胶支架及其制备方法和应用
US12302908B2 (en) 2023-10-23 2025-05-20 Solasta Bio Limited Insect neuropeptides 4
US12245588B1 (en) 2023-10-23 2025-03-11 Solasta Bio Limited Insect neuropeptides 2
US12281143B1 (en) 2023-10-23 2025-04-22 Solasta Bio Limited Insect neuropeptides 1
US12245596B1 (en) * 2023-10-23 2025-03-11 Solasta Bio Limited Insect neuropeptides 8
US12279621B1 (en) 2023-10-23 2025-04-22 Solasta Bio Limited Insect neuropeptides 3
US12356995B2 (en) 2023-10-23 2025-07-15 Solasta Bio Limited Insect neuropeptides 9

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
CH596313A5 (es) 1975-05-30 1978-03-15 Battelle Memorial Institute
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
US6932968B1 (en) 1989-07-26 2005-08-23 Dade Behring Marburg Gmbh Erythropoietin (EPO) peptides and antibodies directed against these
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US6849602B1 (en) 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
US6271196B1 (en) 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
US6346390B1 (en) 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US5952293A (en) 1996-03-08 1999-09-14 Receptron Receptor derived peptides involved in inhibition of receptor internalization in response to ligand binding
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
KR101012932B1 (ko) 1999-04-13 2011-02-08 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
AU2001252650A1 (en) 2000-04-28 2001-11-12 Effector Cell Institute Novel derivative of cell chemotactic factor
JP2003534384A (ja) * 2000-05-26 2003-11-18 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経保護性ペプチド
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
WO2002043572A2 (en) 2000-11-30 2002-06-06 Henry M. Jackson Foundation Erythropoietin and erythropoietin receptor expression in human cancer
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
KR20050033563A (ko) 2002-06-28 2005-04-12 센토코 인코포레이티드 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도
EP1552298A4 (en) * 2002-07-01 2006-11-08 Kenneth S Warren Inst Inc RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
CN1729015A (zh) 2002-09-09 2006-02-01 沃伦药品公司 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素
JP2004305006A (ja) 2003-04-01 2004-11-04 Japan Science & Technology Agency 人工調製肺サーファクタント
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
AP2042A (en) 2003-05-12 2009-09-07 Affymax Inc Novel peptides that bind to the erythropoietin receptor
US20070275871A1 (en) 2003-08-28 2007-11-29 Biorexis Technology, Inc. Epo Mimetic Peptides and Fusion Proteins
BRPI0409650A (pt) 2003-09-09 2006-04-25 Warren Pharmaceuticals Inc métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica
ZA200603396B (en) 2003-09-29 2007-11-28 Warren Pharmaceuticals Inc Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US20050090551A1 (en) 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
EP2992901B1 (en) 2004-02-02 2019-10-23 EnGeneIC Molecular Delivery Pty Ltd Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
WO2005089269A2 (en) * 2004-03-16 2005-09-29 Temple University - Of The Commonwealth System Of Higher Education Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
US20050267027A1 (en) 2004-04-05 2005-12-01 Lounsbury Karen M Use of erythropoietin for treatment of cancer
WO2007010552A2 (en) * 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP2377884A1 (en) 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
WO2006127910A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
PL2540309T3 (pl) 2005-08-05 2018-03-30 Araim Pharmaceuticals, Inc. Peptydy chroniące tkanki i ich zastosowanie
EP2121740A2 (en) 2005-12-20 2009-11-25 Copenhagen University Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
WO2008076819A2 (en) 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
JP5542064B2 (ja) 2008-01-22 2014-07-09 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体

Also Published As

Publication number Publication date
CN104689298A (zh) 2015-06-10
KR101768792B1 (ko) 2017-08-16
NZ621196A (en) 2015-08-28
PL2245056T3 (pl) 2015-08-31
KR20170049616A (ko) 2017-05-10
JP2014169308A (ja) 2014-09-18
US20170232066A1 (en) 2017-08-17
KR20180041269A (ko) 2018-04-23
KR101850908B1 (ko) 2018-04-20
US20200360476A1 (en) 2020-11-19
SG10201604530SA (en) 2016-07-28
US20150239932A1 (en) 2015-08-27
JP2017002040A (ja) 2017-01-05
EP2245056A2 (en) 2010-11-03
JP5542064B2 (ja) 2014-07-09
SG188161A1 (en) 2013-03-28
EP2245056B1 (en) 2015-03-11
ES2539124T3 (es) 2015-06-26
KR20180123731A (ko) 2018-11-19
JP2011527560A (ja) 2011-11-04
EP2933264A3 (en) 2015-12-09
JP2021073281A (ja) 2021-05-13
AU2009206748A1 (en) 2009-07-30
CN108743916A (zh) 2018-11-06
KR20150134442A (ko) 2015-12-01
HK1215713A1 (en) 2016-09-09
KR101572286B1 (ko) 2015-11-27
NZ601868A (en) 2014-05-30
HK1143822A1 (en) 2011-01-14
MX2019011592A (es) 2019-11-21
AU2009206748B2 (en) 2014-03-20
CN102066413A (zh) 2011-05-18
CN102066413B (zh) 2015-01-21
IL207155A (en) 2015-07-30
US9580465B2 (en) 2017-02-28
JP6309815B2 (ja) 2018-04-11
US20110263504A1 (en) 2011-10-27
WO2009094172A2 (en) 2009-07-30
KR20190085187A (ko) 2019-07-17
WO2009094172A3 (en) 2009-12-10
CA2712757A1 (en) 2009-07-30
EP2933264A2 (en) 2015-10-21
US8853358B2 (en) 2014-10-07
IL207155A0 (en) 2010-12-30
MX2010008050A (es) 2011-02-23
PL2245056T4 (pl) 2016-01-29
JP2019123715A (ja) 2019-07-25
SG10202011946PA (en) 2020-12-30
NZ587105A (en) 2012-09-28
CN111346213A (zh) 2020-06-30
KR20100117616A (ko) 2010-11-03
KR20200075044A (ko) 2020-06-25

Similar Documents

Publication Publication Date Title
MX2019011592A (es) Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
AU2018253546A1 (en) Aromatic-cationic peptides and methods for using same
MX2012009748A (es) USO DE PEPTIDOS INHIBIDORES DEL FACTOR DE CRECIMIENTO TRANSFORMANTE-BETA1(TGF-ß1) PARA EL TRATAMIENTO DE FIBROSIS Y/U OPACIDAD CORNEAL.
SG10201809099PA (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ611108A (en) Methods of treating fgf21-associated disorders
HK1215934A1 (zh) 肽治疗剂及其使用方法
NZ593474A (en) Compositions and methods for treatment of celiac disease
MX357801B (es) Agentes dirigidos a gadd45beta.
ECSP10010288A (es) Vectores de virus oncolíticos de viruela
PT1854477T (pt) Inibidores peptidicos da calicreína plasmática e sua utilização no tratamento de doenças oftalmológicas
PH12015500186A1 (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
EP4285994A3 (en) Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
MY167232A (en) Polypeptides binding to human complement c5
MY167804A (en) Treatment of degenerative joint disease
EP2166845A4 (en) ALPHA CONNEXIN C TERMINAL (ACT) PEPTIDES FOR THE TREATMENT OF AGE-RELATED MACULAR AGENCY
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
IN2015DN00585A (es)
MY178169A (en) Topical ophthalmic peptide formulation
EP2552462A4 (en) CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS
WO2014039074A3 (en) Therapeutic compositions and related methods
TN2009000135A1 (en) Use of modified cyclosporins
EP2566502A4 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
WO2012090207A3 (en) Par1 and par2 c-tail peptides and peptide mimetics
WO2017189988A8 (en) Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
MX2013003903A (es) Nuevos tratamientos de infeccion por el virus de hepatitis c.